Methods: In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design on three dosing schedules: daily x 5 every 3 weeks, daily x 3 every 3 weeks or …

Cybrexa has synthesized and developed CBX-12, an alphalexTM conjugate of the potent topoisomerase inhibitor, exatecan. CBX-12 provides additional proof of mechanism to the …

CBX-12-101: A first-in-human study of CBX-12, an alphalexTM peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors 1 The University of Texas MD Anderson …

CBX-12 consists of the pH-sensitive peptide, a self-immolating linker, and the topoisomerase 1 (TOP1) inhibitor exatecan. Method: In a Phase 1 trial, cohorts of patients were treated with …

2024年5月29日 · CBX-12 is a peptide conjugate that uses a novel pH-low insertion peptide (pHLIP) linked to TOP1 inhibitor exatecan to selectively target the low-pH tumor …

CBX-12 is an alphalex TM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 has demonstrated strong efficacy and a solid safety profile in preclinical …

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. Background: Tumor-targeted drug …

2023年1月4日 · CBX-12 is a novel peptide-drug agent targeting the TOP1-inhibiting drug exatecan to tumor via pH-sensitive peptide. Unlike tumor targeting via antibody, CBX-12 …

2020年8月15日 · We report the discovery and development of CBX-12, an alphalex TM conjugate of the potent topoisomerase inhibitor, exatecan. CBX-12 provides additional proof of …

2021年12月1日 · CBX-12 is administered as a 1-hour intravenous infusion. Two dosing schedules, daily x 5 every 3 weeks (Part A) and daily x 3 every 3 weeks (Part B), are being …